Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA.

Science. 2018 Jan 5;359(6371):97-103. doi: 10.1126/science.aan4236. Epub 2017 Nov 2.

2.

The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.

Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, Luke JJ, Gajewski TF.

Science. 2018 Jan 5;359(6371):104-108. doi: 10.1126/science.aao3290.

PMID:
29302014
3.

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L.

Science. 2018 Jan 5;359(6371):91-97. doi: 10.1126/science.aan3706. Epub 2017 Nov 2.

PMID:
29097494
4.

Gut microbiome and immunotherapy response.

Burki TK.

Lancet Oncol. 2017 Dec;18(12):e717. doi: 10.1016/S1470-2045(17)30841-0. Epub 2017 Nov 9. No abstract available.

PMID:
29129446
5.

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.

Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre ML, Chang EB, Gajewski TF.

Science. 2015 Nov 27;350(6264):1084-9. doi: 10.1126/science.aac4255. Epub 2015 Nov 5.

6.

Immunotherapy Not Working? Check Your Microbiota.

West NR, Powrie F.

Cancer Cell. 2015 Dec 14;28(6):687-689. doi: 10.1016/j.ccell.2015.11.010.

7.

Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.

Gentzler R, Hall R, Kunk PR, Gaughan E, Dillon P, Slingluff CL Jr, Rahma OE.

Immunotherapy. 2016 May;8(5):583-600. doi: 10.2217/imt-2015-0029. Review.

PMID:
27140411
8.

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.

Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP, Poirier-Colame V, Roux A, Becharef S, Formenti S, Golden E, Cording S, Eberl G, Schlitzer A, Ginhoux F, Mani S, Yamazaki T, Jacquelot N, Enot DP, Bérard M, Nigou J, Opolon P, Eggermont A, Woerther PL, Chachaty E, Chaput N, Robert C, Mateus C, Kroemer G, Raoult D, Boneca IG, Carbonnel F, Chamaillard M, Zitvogel L.

Science. 2015 Nov 27;350(6264):1079-84. doi: 10.1126/science.aad1329. Epub 2015 Nov 5.

9.

Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.

Komatsubara KM, Carvajal RD.

Curr Oncol Rep. 2017 Jul;19(7):45. doi: 10.1007/s11912-017-0606-5. Review.

PMID:
28508938
10.

Gut microbes shape response to cancer immunotherapy.

Kaiser J.

Science. 2017 Nov 3;358(6363):573. doi: 10.1126/science.358.6363.573. No abstract available.

PMID:
29097525
11.

IMMUNOTHERAPY. Could microbial therapy boost cancer immunotherapy?

Snyder A, Pamer E, Wolchok J.

Science. 2015 Nov 27;350(6264):1031-2. doi: 10.1126/science.aad7706. No abstract available.

PMID:
26612936
12.

Immunotherapy of melanoma.

Kee D, McArthur G.

Eur J Surg Oncol. 2017 Mar;43(3):594-603. doi: 10.1016/j.ejso.2016.07.014. Epub 2016 Aug 2.

PMID:
27514721
13.

Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients.

Frankel AE, Coughlin LA, Kim J, Froehlich TW, Xie Y, Frenkel EP, Koh AY.

Neoplasia. 2017 Oct;19(10):848-855. doi: 10.1016/j.neo.2017.08.004. Epub 2017 Sep 15.

14.

Gut Microbiota Promotes Tumor Growth in Mice by Modulating Immune Response.

Sethi V, Kurtom S, Tarique M, Lavania S, Malchiodi Z, Hellmund L, Zhang L, Sharma U, Giri B, Garg B, Ferrantella A, Vickers SM, Banerjee S, Dawra R, Roy S, Ramakrishnan S, Saluja A, Dudeja V.

Gastroenterology. 2018 Jul;155(1):33-37.e6. doi: 10.1053/j.gastro.2018.04.001. Epub 2018 Apr 7.

PMID:
29630898
15.

Fine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome.

Pitt JM, Vétizou M, Waldschmitt N, Kroemer G, Chamaillard M, Boneca IG, Zitvogel L.

Cancer Res. 2016 Aug 15;76(16):4602-7. doi: 10.1158/0008-5472.CAN-16-0448. Epub 2016 Jul 29. Review.

16.

Immunotherapy in melanoma: Recent advances and future directions.

Franklin C, Livingstone E, Roesch A, Schilling B, Schadendorf D.

Eur J Surg Oncol. 2017 Mar;43(3):604-611. doi: 10.1016/j.ejso.2016.07.145. Epub 2016 Sep 2. Review.

PMID:
27769635
17.

GUTSS: An Alignment-Free Sequence Comparison Method for Use in Human Intestinal Microbiome and Fecal Microbiota Transplantation Analysis.

Brittnacher MJ, Heltshe SL, Hayden HS, Radey MC, Weiss EJ, Damman CJ, Zisman TL, Suskind DL, Miller SI.

PLoS One. 2016 Jul 8;11(7):e0158897. doi: 10.1371/journal.pone.0158897. eCollection 2016.

18.

Immune checkpoint blockade.

Naidoo J, Page DB, Wolchok JD.

Hematol Oncol Clin North Am. 2014 Jun;28(3):585-600. doi: 10.1016/j.hoc.2014.02.002. Review.

PMID:
24880949
19.

Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition.

Lau PK, Ascierto PA, McArthur G.

Curr Opin Immunol. 2016 Apr;39:30-8. doi: 10.1016/j.coi.2015.12.006. Epub 2016 Jan 5. Review.

PMID:
26765776
20.

Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment.

Botticelli A, Zizzari I, Mazzuca F, Ascierto PA, Putignani L, Marchetti L, Napoletano C, Nuti M, Marchetti P.

Oncotarget. 2017 Jan 31;8(5):8890-8899. doi: 10.18632/oncotarget.12985. Review.

Supplemental Content

Support Center